Incorporating Assessments of Sequence-Dependence in Developmental Studies of Combination Chemotherapy Regimens Containing New Agents and Platinum Compounds

1996 ◽  
pp. 205-220
Author(s):  
Eric K. Rowinsky
Keyword(s):  
Combination Chemotherapy ◽  
Developmental Studies ◽  
Platinum Compounds ◽  
Sequence Dependence ◽  
New Agents

scholarly journals Side effects of combination chemotherapy with fluorouracil and platinum compounds in oral cancer.

1997 ◽  
Vol 43 (12) ◽  
pp. 912-914
Author(s):  
Masayasu IWASE ◽  
Yutaka KUME ◽  
Nobuko ITO ◽  
Masato HORI ◽  
Yoichi KURACHI ◽  
...  
Keyword(s):  
Side Effects ◽  
Oral Cancer ◽  
Combination Chemotherapy ◽  
Platinum Compounds

scholarly journals Combination Chemotherapy with Doxorubicin, Vincristine, Cyclophosphamide, and Platinum Compounds for Advanced Thymic Carcinoma

2011 ◽  
Vol 6 (12) ◽  
pp. 2130-2134 ◽  
Author(s):  
Toshihiko Agatsuma ◽  
Tomonobu Koizumi ◽  
Shintaro Kanda ◽  
Michiko Ito ◽  
Kazuhisa Urushihata ◽  
...  
Keyword(s):  
Combination Chemotherapy ◽  
Thymic Carcinoma ◽  
Platinum Compounds

Oxaliplatin and Raltitrexed in the Treatment of Inoperable Malignant Pleural Mesothelioma: Results of a Pilot Study

2001 ◽  
Vol 87 (6) ◽  
pp. 391-393 ◽  
Author(s):  
Roberto Maisano ◽  
Nicola Caristi ◽  
Giuseppe Toscano ◽  
Marcello Aragona ◽  
Pietro Spadaro ◽  
...  
Keyword(s):  
Pilot Study ◽  
Phase I ◽  
Malignant Pleural Mesothelioma ◽  
Combination Chemotherapy ◽  
Phase I Study ◽  
Response Rate ◽  
Objective Response ◽  
Pleural Mesothelioma ◽  
New Agents ◽  
To Receive

Aims and Background The treatment of inoperable malignant pleural mesothelioma is a challenge for the oncologist. Available chemotherapy regimens achieve poor results, therefore new agents or combinations are needed. In a phase I study, the combination of oxaliplatin and raltitrexed was shown to be active against malignant pleural mesothelioma. We herein report the results of a pilot study about the treatment of this disease. Methods From April 1999 to June 2000, we enrolled 11 chemotherapy-naïve patients with inoperable malignant pleural mesothelioma suitable to receive the following combination chemotherapy: raltitrexed, 3 mg/m2 iv, and oxaliplatin, 130 mg/m2, as a 2-hr infusion every 3 weeks. Results Four partial responses, 1 regression of disease (objective response rate, 45%; 95% Cl, 15.6-74.4%), 4 stable diseases and 2 progressions of disease were observed. An improvement in disease-related symptoms was recorded in all responders and in 2 patients with stable disease. Toxicity was mild, with no toxic-related death and only 1 episode of grade 4 neurotoxicity. Conclusions We consider the combination promising and worthy of further studies.

Combination Chemotherapy of L1210 Leukemia With Platinum Compounds and Cyclophosphamide Plus Other Selected Antineoplastic Agents 2

1976 ◽  
Vol 57 (6) ◽  
pp. 1363-1366 ◽  
Author(s):  
Glen R. Gale ◽  
Loretta M. Atkins ◽  
Sandra J. Meischen ◽  
Alayne B. Smith ◽  
Ernest M. Walker
Keyword(s):  
Combination Chemotherapy ◽  
Antineoplastic Agents ◽  
Platinum Compounds ◽  
L1210 Leukemia

Platinum Compounds as Stains for Electron Microscopy

1974 ◽  
Vol 32 ◽  
pp. 230-231
Author(s):  
S. K. Aggarwal ◽  
P. McAllister ◽  
R. W. Wagner ◽  
B. Rosenberg
Keyword(s):  
Electron Microscopy ◽  
Hela Cells ◽  
Uranyl Acetate ◽  
Sarcoma 180 ◽  
Platinum Compounds ◽  
Kb Cells ◽  
En Bloc ◽  
Human Lymphoma ◽  
Ultrathin Sections ◽  
Blue Coloration

Uranyl acetate has been used as an electron stain for en bloc staining as well as for staining ultrathin sections in conjunction with various lead stains (Fig. 1). Present studies reveal that various platinum compounds also show promise as electron stains. Certain platinum compounds have been shown to be effective anti-tumor agents. Of particular interest are the compounds with either uracil or thymine as one of the ligands (cis-Pt(II)-uracil; cis-Pt(II)-thymine). These compounds are amorphous, highly soluble in water and often exhibit an intense blue coloration. These compounds show enough electron density to be used as stains for electron microscopy. Most of the studies are based on various cell lines (human AV, cells, human lymphoma cells, KB cells, Sarcoma-180 ascites cells, chick fibroblasts and HeLa cells) while studies on tissue blocks are in progress.

Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity

2019 ◽  
Vol 476 (24) ◽  
pp. 3705-3719 ◽  
Author(s):  
Avani Vyas ◽  
Umamaheswar Duvvuri ◽  
Kirill Kiselyov
Keyword(s):  
Oxidative Stress ◽  
Head And Neck ◽  
Transcriptional Activation ◽  
Platinum Resistance ◽  
Mrna Levels ◽  
Strong Positive Correlation ◽  
Platinum Compounds ◽  
Copper Chelation ◽  
Novel Approach ◽  
Cancer Models

Platinum-containing drugs such as cisplatin and carboplatin are routinely used for the treatment of many solid tumors including squamous cell carcinoma of the head and neck (SCCHN). However, SCCHN resistance to platinum compounds is well documented. The resistance to platinum has been linked to the activity of divalent transporter ATP7B, which pumps platinum from the cytoplasm into lysosomes, decreasing its concentration in the cytoplasm. Several cancer models show increased expression of ATP7B; however, the reason for such an increase is not known. Here we show a strong positive correlation between mRNA levels of TMEM16A and ATP7B in human SCCHN tumors. TMEM16A overexpression and depletion in SCCHN cell lines caused parallel changes in the ATP7B mRNA levels. The ATP7B increase in TMEM16A-overexpressing cells was reversed by suppression of NADPH oxidase 2 (NOX2), by the antioxidant N-Acetyl-Cysteine (NAC) and by copper chelation using cuprizone and bathocuproine sulphonate (BCS). Pretreatment with either chelator significantly increased cisplatin's sensitivity, particularly in the context of TMEM16A overexpression. We propose that increased oxidative stress in TMEM16A-overexpressing cells liberates the chelated copper in the cytoplasm, leading to the transcriptional activation of ATP7B expression. This, in turn, decreases the efficacy of platinum compounds by promoting their vesicular sequestration. We think that such a new explanation of the mechanism of SCCHN tumors’ platinum resistance identifies novel approach to treating these tumors.

New Agents for Gout Provide Alternatives to Allopurinol

2009 ◽  
Vol 42 (2) ◽  
pp. 13
Author(s):  
NANCY WALSH
Keyword(s):  
New Agents

Evaluations of Combination Chemotherapy(DAC-Tam) for Advanced Malignant Melanoma. Possible Patient Groups which may Show a Good Response Rate.

2001 ◽  
Vol 63 (5) ◽  
pp. 561-568
Author(s):  
Hideki KAMIYA ◽  
Hiroyuki KANOH ◽  
Naoki ICHIHASHI ◽  
Yoshiro ICHIKI ◽  
Hajime TAKAGI ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Combination Chemotherapy ◽  
Response Rate ◽  
Good Response Rate ◽  
Advanced Malignant Melanoma ◽  
Patient Groups
Sign in / Sign up

Export Citation Format

Share Document